Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 13/20 | 0.59 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5992360 | 0.78 | VCAM1 (0.60) | VCAM1TDP1TSHRMAPK1 | |
| SCHEMBL358730 | 0.78 | MAPK1 (0.69) | VCAM1TDP1TSHRMAPK1 | |
| SCHEMBL29394047 | 0.78 | MAPK1 (0.69) | VCAM1TDP1TSHRMAPK1 | |
| SCHEMBL2461199 | 0.77 | VCAM1 (0.58) | VCAM1TDP1TSHRMAPK1 | |
| Dinitrochlorobenzene SCHEMBL29349476 | 0.77 | HSD17B10 (0.69) | VCAM1TDP1TSHRMAPK1HSD17B10 | |
| Ammonia Solution, Strong SCHEMBL28805237 | 0.77 | MAPK1 (0.67) | VCAM1TDP1TSHRMAPK1 | |
| Dinitrochlorobenzene SCHEMBL39251 | 0.77 | HSD17B10 (0.69) | VCAM1TDP1TSHRMAPK1HSD17B10 | |
| Dinitrochlorobenzene SCHEMBL20472381 | 0.77 | HSD17B10 (0.69) | VCAM1TDP1TSHRMAPK1HSD17B10 | |
| SCHEMBL14924313 | 0.75 | VCAM1 (0.56) | VCAM1TDP1TSHRMAPK1NPBWR1 | |
| SCHEMBL539833 | 0.75 | VCAM1 (0.56) | VCAM1TDP1TSHRMAPK1NPBWR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188282-B2 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2012-05-29 | — | — | US | disclosed |
| EP-2044033-B1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI SA (FR) | 2012-02-08 | — | — | EP | disclosed |
| CN-101490014-B | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2011-12-14 | — | — | CN | disclosed |
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI-AVENTIS (FR) | 2009-08-13 | — | — | US | disclosed |
| CN-101490014-A | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | SANOFI AVENTIS (FR) | 2009-07-22 | — | — | CN | disclosed |
| EP-2044033-A1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | Sanofi-Aventis (FR) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008009348-A1 | A REGIOSELECTIVE PALLADIUM CATALYZED SYNTHESIS OF BENZIMIDAZOLES AND AZABENZIMIDAZOLES | SANOFI-AVENTIS (FR) | 2008-01-24 | — | — | WO | disclosed |
| EP-1878724-A1 | A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | sanofi-aventis (FR) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090203912-A1 | Regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles | DDT, NIT2, PADI1 | VCAM1 4666/4885TDP1 2194/4885TSHR 1289/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.